Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Annals of Hematology
Erschienen in: Annals of Hematology 4/2019

07.12.2018 | Original Article

(R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study

verfasst von: A. Collignon, C. Houillier, G. Ahle, O. Chinot, S. Choquet, A. Schmitt, P. Agape, C. Soussain, K. Hoang-Xuan, Emeline Tabouret

Erschienen in: Annals of Hematology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Recurrent primary central nervous system lymphomas (PCNSL) have a very poor prognosis. For young and fit patients, intensive chemotherapy followed by autologous stem cell transplantation could be proposed at relapse. In the other cases (unfit or elderly patients), therapeutic options are limited with no consensual regimen. The poly-chemotherapy by (R)-GEMOX is associated with anti-tumor activity in systemic lymphomas and a favorable toxicity profile. Our objective was to evaluate the activity and tolerance of (R)-GEMOX in PCNSL patients enrolled in the French nation-wide LOC cohort. We retrospectively analyzed all refractory or recurrent patients included in the LOC network who benefited from (R)-GEMOX (rituximab 375 mg/m2, gemcitabine 1000 mg/m2, and oxaliplatine 100 mg/m2). Administration, tolerance, and efficacy data were analyzed. Thirteen patients, treated in five different institutions, benefited from the (R)-GEMOX regimen from February 2013 to August 2017. At the initiation of (R)-GEMOX, median age was 71.4 years old (range, 49.5–82.5) and median Karnofsky performance status (KPS) was 60 (range, 40–80). Seven patients were in second line of treatment whereas the six others were in third line or over. All patients had received methotrexate-based polychemotherapy as first-line treatment except one. Overall response rate was 38% with two complete responses and three partial responses. Median progression-free survival was 3.2 months (95%CI: 0.2–6.2), and median overall survival was 8.2 months (95%CI: 0.6–15.8). Toxicity was mainly hematological including grade ¾ neutropenia (38%), lymphopenia (23%), and thrombopenia (23%). Older age (p = 0.046) and low KPS (p = 0.054) tended to be associated with a worse prognosis. (R)-GEMOX is associated with substantial response rate and favorable toxicity profile in unfit patients with recurrent PCNSL. (R)-GEMOX could be considered to be an additional option in patients with recurrent/refractory PCNSL.
Literatur
1.
Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ (2011) Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 105(9):1414–1418CrossRefPubMedPubMedCentral
2.
3.
Ferreri AJM, Blay J-Y, Reni M, Pasini F, Spina M, Ambrosetti A et al (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol Off J Am Soc Clin Oncol 21(2):266–272CrossRef
4.
Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W et al (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24(36):5711–5715CrossRefPubMed
5.
McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR et al (2000) Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46(1):51–60 discussion 60-61CrossRefPubMed
6.
Batchelor T, Carson K, O’Neill A, Grossman SA, Alavi J, New P et al (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96–07. J Clin Oncol Off J Am Soc Clin Oncol 21(6):1044–1049CrossRef
7.
Roth P, Hoang-Xuan K (2014) Challenges in the treatment of elderly patients with primary central nervous system lymphoma. Curr Opin Neurol 27(6):697–701CrossRefPubMed
8.
Zhu J-J, Gerstner ER, Engler DA, Mrugala MM, Nugent W, Nierenberg K, Hochberg FH, Betensky RA, Batchelor TT (2009) High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro-Oncol 11(2):211–215CrossRefPubMedPubMedCentral
9.
10.
Welch MR, Omuro A, Deangelis LM (2012) Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neuro-Oncol 14(10):1304–1311CrossRefPubMedPubMedCentral
11.
Roth P, Martus P, Kiewe P, Möhle R, Klasen H, Rauch M et al (2012) Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology 79(9):890–896CrossRefPubMed
12.
Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, Soubeyran P, Lamy T, Morschhauser F, Benouaich-Amiel A, Ahle G, Moles-Moreau MP, Moluçon-Chabrot C, Bourquard P, Damaj G, Jardin F, Larrieu D, Gyan E, Gressin R, Jaccard A, Choquet S, Brion A, Casasnovas O, Colin P, Reman O, Tempescul A, Marolleau JP, Fabbro M, Naudet F, Hoang-Xuan K, Houot R (2016) Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro-Oncol 18(9):1297–1303CrossRefPubMedPubMedCentral
13.
Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L, Korfel A, on behalf of the German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG) (2006) Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol 80(2):159–165CrossRefPubMed
14.
Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F et al (2008) Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol Off J Am Soc Clin Oncol 26(15):2512–2518CrossRef
15.
Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB et al (2004) Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res Off J Am Assoc Cancer Res 10(17):5643–5646CrossRef
16.
Pentsova E, Deangelis LM, Omuro A (2014) Methotrexate re-challenge for recurrent primary central nervous system lymphoma. J Neurooncol 117(1):161–165CrossRefPubMedPubMedCentral
17.
Gaviani P, Simonetti G, Innocenti A, Lamperti E, Botturi A, Silvani A (2016) Safety and efficacy of primary central nervous system lymphoma treatment in elderly population. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 37(1):131–133
18.
19.
Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE (2007) Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 69(11):1178–1182CrossRefPubMed
20.
López A, Gutiérrez A, Palacios A, Blancas I, Navarrete M, Morey M et al (2008) GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol 80(2):127–132CrossRefPubMed
21.
Abrey LE, Batchelor TT, Ferreri AJM, Gospodarowicz M, Pulczynski EJ, Zucca E et al (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 23(22):5034–5043CrossRef
22.
23.
Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M et al (2007) Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 96(6):864–867CrossRefPubMedPubMedCentral
24.
Makino K, Nakamura H, Hide T-I, Kuratsu J-I (2012) Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status. J Neurooncol 106(1):155–160CrossRefPubMed
25.
Enting RH, Demopoulos A, DeAngelis LM, Abrey LE (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63(5):901–903CrossRefPubMed
26.
Wong ET, Tishler R, Barron L, Wu JK (2004) Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 101(1):139–145CrossRefPubMed
27.
Kim Y-J, Choe J-H, Park J-H, Hong Y-K (2015) Efficacy of Procarbazine, Lomustine, and vincristine chemotherapy for recurrent primary central nervous system lymphomas. Brain Tumor Res Treat 3(2):75–80CrossRefPubMedPubMedCentral
28.
Herrlinger U, Brugger W, Bamberg M, Küker W, Dichgans J, Weller M (2000) PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 54(8):1707–1708CrossRefPubMed
29.
Choquet S, Grenier A, Houillier C, Soussain C, Moles MP, Gastinne T et al (2015) Very High Efficiency of ICE (Ifosfamide-Carboplatin-Etoposide) in Relapse/Refractory (R/R) Primary Central Nervous System (PCNSL) and Vitreo-Retinal (VRL) Non Hodgkin Lymphoma. a LOC Network Multicenter Retrospective Study on 58 Cases. Blood 126(23):1524–1524
30.
31.
Illerhaus G, Schorb E, Kasenda B (2018) Novel agents for primary central nervous system lymphoma: evidence and perspectives. Blood 132(7):681–688CrossRefPubMed
32.
Ghesquieres H, Houillier C, Chinot O, Choquet S, Molucon-Chabrot C, Beauchene P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Chevrier M, Savignoni A, Turbiez I, Veillas F, Soumelis V, Soussain C (2016) Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a « Proof of Concept » Phase II Study of the French LOC Network. Blood
33.
Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J et al (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2(13):1595–1607CrossRefPubMedPubMedCentral
34.
Chamoun K, Choquet S, Boyle E, Houillier C, Larrieu-Ciron D, Al Jijakli A et al (2017) Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: a retrospective case series. Neurology 88(1):101–102CrossRefPubMed
35.
Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK (2017) Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov 7(9):1018–1029CrossRefPubMedPubMedCentral
36.
Choquet S, Houllier C, Bijou F et al (2016) Ibrutinib monotherapy in relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL). Result of the interim analysis of the iLOC phase II Study from the Lysa and the French LOC Network [abstract]. Blood
37.
Chapuy B, Roemer MGM, Stewart C, Tan Y, Abo RP, Zhang L et al (2016) Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127(7):869–881CrossRefPubMedPubMedCentral
38.
Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B et al (2017) PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood 129(23):3071–3073CrossRefPubMedPubMedCentral
39.
40.
Corazzelli G, Capobianco G, Arcamone M, Ballerini PF, Iannitto E, Russo F, Frigeri F, Becchimanzi C, Marcacci G, de Chiara A, Pinto A (2009) Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol 64(5):907–916CrossRefPubMed
41.
Mounier N, El Gnaoui T, Tilly H, Canioni D, Sebban C, Casasnovas R-O et al (2013) Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica nov 98(11):1726–1731CrossRef
42.
Faivre S, Raymond E, Woynarowski JM, Cvitkovic E (1999) Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 44(2):117–123CrossRefPubMed
43.
Smith MR, Joshi I, Jin F, Obasaju C (2005) Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin’s lymphoma cell lines in vitro and in scid mice. BMC Cancer 5:103CrossRefPubMedPubMedCentral
44.
Jacobs S, McCully CL, Murphy RF, Bacher J, Balis FM, Fox E (2010) Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates. Cancer Chemother Pharmacol 65(5):817–824CrossRefPubMed
45.
Stukov AN, Filatova LV, Latipova DK, Bespalov VG, Belyaeva OA, Kireeva GS et al (2015) Therapeutic activity of gemcitabine in intracranial tumors. Vopr Onkol 61(2):274–279PubMed
46.
Petereit HF, Rubbert-Roth A (2009) Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler Houndmills Basingstoke Engl 15(2):189–192CrossRef
Metadaten
Titel
(R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study
verfasst von
A. Collignon
C. Houillier
G. Ahle
O. Chinot
S. Choquet
A. Schmitt
P. Agape
C. Soussain
K. Hoang-Xuan
Emeline Tabouret
Publikationsdatum
07.12.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 4/2019
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-018-3564-6

Weitere Artikel der Ausgabe 4/2019

Annals of Hematology 4/2019 Zur Ausgabe

Original Article

Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis

Original Article

Role of platelets in thrombin generation amongst patients with non-transfusion-dependent thalassaemia

Original Article

Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era

Original Article

Common fetal hemoglobin variants in Lebanese patients bearing the codon 29 beta gene mutation associated with different thalassemia phenotypes

Letter to the Editor

High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease

Letter to the Editor

An under-recognized cause of copper deficiency mimicking myelodysplastic syndrome

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise